Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2014

Open Access 01-12-2014 | Research

Major components of metabolic syndrome and adiponectin levels: a cross-sectional study

Authors: Anize D von Frankenberg, Filipe V do Nascimento, Lucas Eduardo Gatelli, Bárbara L Nedel, Sheila P Garcia, Carolina SV de Oliveira, Pedro Saddi-Rosa, André F Reis, Luis H Canani, Fernando Gerchman

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Login to get access

Abstract

Background

Adiponectin is a major regulator of glucose and lipid homeostasis by its insulin sensitizer properties. Since decreased insulin sensitivity is linked to metabolic syndrome (MS), decreased adiponectin levels may be related to its development. The purpose of the study was to investigate the relationship between adiponectin levels and MS.

Methods

Firstly, we cross-sectionally examined subjects with or without MS submitted to an oral glucose tolerance test at Hospital de Clínicas de Porto Alegre (n = 172). A replication analysis was performed in subjects (n = 422) undergoing cardiac angiography at Hospital São Paulo. Subchronic inflammation (US-CRP), coagulation marker (fibrinogen), insulin sensitivity and resistance (Matsuda ISI and HOMA-IR) were estimated. Plasma total and high molecular weight (HMW) adiponectin were measured.

Results

Total and HMW adiponectin levels were lower in MS subjects (P < 0.05). Total adiponectin levels were lower in the presence of high waist circumference, low HDL-cholesterol and elevated triglyceride criteria in both samples and by elevated blood pressure and glucose criteria in Porto Alegre. HMW adiponectin levels were lower in the presence of low HDL-cholesterol, elevated triglycerides, and glucose criteria. Total adiponectin levels were positively related with HDL-cholesterol and ISI Matsuda, negatively related with waist circumference, glucose, triglycerides, HOMA-IR, and US-CRP and not related with blood pressure. While adjusting for sex and age, increased adiponectin levels remained associated with a reduced prevalence ratio for MS in both cohorts (P = 0.001).

Conclusions

Adiponectin levels decreased with increasing number of MS criteria, and it is in part determined by its relationship with HDL, triglycerides and abdominal adiposity.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO: Obesity: preventing and managing the global epidemic of obesity. Book Obesity: Preventing and Managing the Global Epidemic of Obesity. Reprinted 2004, Geneva, Switzerland: World Health Organization WHO: Obesity: preventing and managing the global epidemic of obesity. Book Obesity: Preventing and Managing the Global Epidemic of Obesity. Reprinted 2004, Geneva, Switzerland: World Health Organization
2.
go back to reference Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005, 28: 1769-1778. 10.2337/diacare.28.7.1769.CrossRefPubMed Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005, 28: 1769-1778. 10.2337/diacare.28.7.1769.CrossRefPubMed
3.
go back to reference Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004, 110: 1245-1250. 10.1161/01.CIR.0000140677.20606.0E.CrossRefPubMed Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004, 110: 1245-1250. 10.1161/01.CIR.0000140677.20606.0E.CrossRefPubMed
4.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed
5.
go back to reference Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S: Prevalence and trends of metabolic syndrome in the adult US population, 1999-2010. J Am Coll Cardiol. 2013, 62: 697-703. 10.1016/j.jacc.2013.05.064.PubMedCentralCrossRefPubMed Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S: Prevalence and trends of metabolic syndrome in the adult US population, 1999-2010. J Am Coll Cardiol. 2013, 62: 697-703. 10.1016/j.jacc.2013.05.064.PubMedCentralCrossRefPubMed
7.
go back to reference Ahima RS: Metabolic actions of adipocyte hormones: focus on adiponectin. Obesity (Silver Spring). 2006, 14 (Suppl 1): 9S-15S.CrossRef Ahima RS: Metabolic actions of adipocyte hormones: focus on adiponectin. Obesity (Silver Spring). 2006, 14 (Suppl 1): 9S-15S.CrossRef
8.
go back to reference Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT: Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006, 55: 249-259. 10.2337/diabetes.55.01.06.db05-1105.CrossRefPubMed Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT: Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006, 55: 249-259. 10.2337/diabetes.55.01.06.db05-1105.CrossRefPubMed
9.
go back to reference Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999, 257: 79-83. 10.1006/bbrc.1999.0255.CrossRefPubMed Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999, 257: 79-83. 10.1006/bbrc.1999.0255.CrossRefPubMed
10.
go back to reference Oliveira CS, Saddi-Rosa P, Crispim F, Canani LH, Gerchman F, Giuffrida FM, Vieira JG, Velho G, Reis AF: Association of ADIPOQ variants, total and high molecular weight adiponectin levels with coronary artery disease in diabetic and non-diabetic Brazilian subjects. J Diabetes Complications. 2012, 26: 94-98. 10.1016/j.jdiacomp.2012.02.008.CrossRefPubMed Oliveira CS, Saddi-Rosa P, Crispim F, Canani LH, Gerchman F, Giuffrida FM, Vieira JG, Velho G, Reis AF: Association of ADIPOQ variants, total and high molecular weight adiponectin levels with coronary artery disease in diabetic and non-diabetic Brazilian subjects. J Diabetes Complications. 2012, 26: 94-98. 10.1016/j.jdiacomp.2012.02.008.CrossRefPubMed
12.
go back to reference Executive summary: Standards of medical care in diabetes--2010. Diabetes Care. 2010, 33 (Suppl 1): S4-S10. Executive summary: Standards of medical care in diabetes--2010. Diabetes Care. 2010, 33 (Suppl 1): S4-S10.
13.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.CrossRefPubMed
14.
go back to reference Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999, 22: 1462-1470. 10.2337/diacare.22.9.1462.CrossRefPubMed Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999, 22: 1462-1470. 10.2337/diacare.22.9.1462.CrossRefPubMed
15.
go back to reference Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, et al: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005, 294: 1799-1809.PubMed Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, et al: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005, 294: 1799-1809.PubMed
16.
go back to reference Kostapanos M, Florentin M, Elisaf MS, Mikhailidis DP: Hemostatic factors and the metabolic syndrome. Curr Vasc Pharmacol. 2013, 11: 880-905.CrossRefPubMed Kostapanos M, Florentin M, Elisaf MS, Mikhailidis DP: Hemostatic factors and the metabolic syndrome. Curr Vasc Pharmacol. 2013, 11: 880-905.CrossRefPubMed
17.
go back to reference Mente A, Meyre D, Lanktree MB, Heydarpour M, Davis AD, Miller R, Gerstein H, Hegele RA, Yusuf S, Anand SS: Causal relationship between adiponectin and metabolic traits: a mendelian randomization study in a multiethnic population. PLoS One. 2013, 8: e66808-10.1371/journal.pone.0066808.PubMedCentralCrossRefPubMed Mente A, Meyre D, Lanktree MB, Heydarpour M, Davis AD, Miller R, Gerstein H, Hegele RA, Yusuf S, Anand SS: Causal relationship between adiponectin and metabolic traits: a mendelian randomization study in a multiethnic population. PLoS One. 2013, 8: e66808-10.1371/journal.pone.0066808.PubMedCentralCrossRefPubMed
18.
go back to reference Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001, 7: 947-953. 10.1038/90992.CrossRefPubMed Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001, 7: 947-953. 10.1038/90992.CrossRefPubMed
19.
go back to reference Asterholm IW, Scherer PE: Enhanced metabolic flexibility associated with elevated adiponectin levels. Am J Pathol. 2010, 176: 1364-1376. 10.2353/ajpath.2010.090647.PubMedCentralCrossRefPubMed Asterholm IW, Scherer PE: Enhanced metabolic flexibility associated with elevated adiponectin levels. Am J Pathol. 2010, 176: 1364-1376. 10.2353/ajpath.2010.090647.PubMedCentralCrossRefPubMed
20.
go back to reference Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE: Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007, 117: 2621-2637. 10.1172/JCI31021.PubMedCentralCrossRefPubMed Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE: Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007, 117: 2621-2637. 10.1172/JCI31021.PubMedCentralCrossRefPubMed
21.
go back to reference Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J: Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011, 60: 313-326. 10.1016/j.metabol.2010.09.003.CrossRefPubMed Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J: Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011, 60: 313-326. 10.1016/j.metabol.2010.09.003.CrossRefPubMed
22.
go back to reference Shetty S, Ramos-Roman MA, Cho YR, Brown J, Plutzky J, Muise ES, Horton JD, Scherer PE, Parks EJ: Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology. 2012, 153: 113-122. 10.1210/en.2011-1339.PubMedCentralCrossRefPubMed Shetty S, Ramos-Roman MA, Cho YR, Brown J, Plutzky J, Muise ES, Horton JD, Scherer PE, Parks EJ: Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology. 2012, 153: 113-122. 10.1210/en.2011-1339.PubMedCentralCrossRefPubMed
23.
go back to reference Chen MB, McAinch AJ, Macaulay SL, Castelli LA, O'Brien PE, Dixon JB, Cameron-Smith D, Kemp BE, Steinberg GR: Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab. 2005, 90: 3665-3672. 10.1210/jc.2004-1980.CrossRefPubMed Chen MB, McAinch AJ, Macaulay SL, Castelli LA, O'Brien PE, Dixon JB, Cameron-Smith D, Kemp BE, Steinberg GR: Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab. 2005, 90: 3665-3672. 10.1210/jc.2004-1980.CrossRefPubMed
24.
go back to reference Debard C, Laville M, Berbe V, Loizon E, Guillet C, Morio-Liondore B, Boirie Y, Vidal H: Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of Type 2 diabetic patients. Diabetologia. 2004, 47: 917-925. 10.1007/s00125-004-1394-7.CrossRefPubMed Debard C, Laville M, Berbe V, Loizon E, Guillet C, Morio-Liondore B, Boirie Y, Vidal H: Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of Type 2 diabetic patients. Diabetologia. 2004, 47: 917-925. 10.1007/s00125-004-1394-7.CrossRefPubMed
25.
go back to reference Fuentes E, Fuentes F, Vilahur G, Badimon L, Palomo I: Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm. 2013, 2013: 136584-PubMedCentralPubMed Fuentes E, Fuentes F, Vilahur G, Badimon L, Palomo I: Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm. 2013, 2013: 136584-PubMedCentralPubMed
26.
go back to reference Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF: Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab. 2009, 94: 989-997. 10.1210/jc.2008-1457.CrossRefPubMed Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF: Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab. 2009, 94: 989-997. 10.1210/jc.2008-1457.CrossRefPubMed
27.
go back to reference Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, Gambert P: Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol. 2006, 26: 1364-1369. 10.1161/01.ATV.0000219611.50066.bd.CrossRefPubMed Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, Gambert P: Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol. 2006, 26: 1364-1369. 10.1161/01.ATV.0000219611.50066.bd.CrossRefPubMed
28.
go back to reference Clarenbach JJ, Vega GL, Adams-Huet B, Considine RV, Ricks M, Sumner AE: Variability in postheparin hepatic lipase activity is associated with plasma adiponectin levels in African Americans. J Investig Med. 2007, 55: 187-194. 10.2310/6650.2007.07001.CrossRefPubMed Clarenbach JJ, Vega GL, Adams-Huet B, Considine RV, Ricks M, Sumner AE: Variability in postheparin hepatic lipase activity is associated with plasma adiponectin levels in African Americans. J Investig Med. 2007, 55: 187-194. 10.2310/6650.2007.07001.CrossRefPubMed
29.
go back to reference Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA: Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care. 2005, 28: 2181-2186. 10.2337/diacare.28.9.2181.CrossRefPubMed Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA: Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care. 2005, 28: 2181-2186. 10.2337/diacare.28.9.2181.CrossRefPubMed
Metadata
Title
Major components of metabolic syndrome and adiponectin levels: a cross-sectional study
Authors
Anize D von Frankenberg
Filipe V do Nascimento
Lucas Eduardo Gatelli
Bárbara L Nedel
Sheila P Garcia
Carolina SV de Oliveira
Pedro Saddi-Rosa
André F Reis
Luis H Canani
Fernando Gerchman
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-6-26

Other articles of this Issue 1/2014

Diabetology & Metabolic Syndrome 1/2014 Go to the issue